Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901687 | 0.87 | MGLL (0.43) | ITGB3ITGA2BMGLLMEN1KMT2A | |
| SCHEMBL11769443 | 0.86 | MEN1 (0.48) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL14286049 | 0.86 | MGLL (0.46) | MGLLMEN1KMT2A | |
| SCHEMBL1586984 | 0.84 | MEN1 (0.62) | ITGB3ITGA2BFFAR1MGLLMEN1 | |
| SCHEMBL3754810 | 0.84 | MGLL (0.50) | MGLLMEN1KMT2A | |
| SCHEMBL11770956 | 0.83 | ALDH1A1 (0.41) | MGLLMEN1KMT2A | |
| SCHEMBL30457667 | 0.83 | DHFR (0.45) | MGLLMEN1KMT2A | |
| SCHEMBL28981248 | 0.81 | CALM1 (0.41) | MEN1KMT2A | |
| SCHEMBL30279565 | 0.81 | CALM1 (0.41) | MEN1KMT2A | |
| SCHEMBL24041815 | 0.80 | DHFR (0.40) | MGLLMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772227-A | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-10-15 | — | — | CN | disclosed |
| CN-110799520-B | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-10723952-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20170306233-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170306233-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | SMC4, PHOSPHO1, SMCHD1 | ITGB3 3659/4885ITGA2B 3723/4885FFAR1 2028/4885 |
| US-10723952-B2 | Polymerizable compound and optically anisotropic body | SMC4, SMCHD1, PHOSPHO1 | ITGB3 3505/4885ITGA2B 3739/4885FFAR1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.